We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
TAGRISSO (AstraZeneca Pty Ltd)
Product name
TAGRISSO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
226 (255 working days)
Active ingredients
osimertinib mesilate
Registration type
EOI
Indication
TAGRISSO is indicated in combination with:
- pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 L858R mutations.